anonymous
Guest
anonymous
Guest
It;s a great time to be in diabetes. Look at how many things are going on? There won't be any layoffs. Go do your job and be thankful to be employed.
its a great time, unless you're miserable. This company was so much better 10 years ago. A good ,even bearable culture has morphed into a toxic one. I'd love to go back to the day when access budget was a few hundred dollars per month.
It's more than doubled in past 5-6 years. More access meals, more programs, use all avail resources, increase your call average, more training, more everything....The point is (the workload is much more and the expectations are greater year over year), and for a 2% raise at that. It's not all roses and perfume like most of you people act like it is.
Your brain and body has been trained by AZ to do 20% more year over end
You should run for political office because you are so full of shit that people must be able to smell you from a mile away. This is the simplest, brainless job that a even the UPS man could handle it with less than one day of training. Just go thru the ridiculous and worthless steps every day and keep your nose clean because you will never find an easier job that pays this well.
It’s time....jump inGoing to sit by a lake today.....
Sounds like a winner to me! Can’t believe that AZ is still toughing it out and competing in the Diabetes market. It’s time for AZ to unfriend Diabetes.Novo's oral semaglutide will hit the market by September. Who thinks we'll be out of jobs by then?
In Novo's Pioneer study, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck's Januvia (sitagliptin), Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin), and Novo's own daily GLP-1 injection Victoza (liraglutide) as well as placebo.
Sounds like a winner to me! Can’t believe that AZ is still toughing it out and competing in the Diabetes market. It’s time for AZ to unfriend Diabetes.
If you can’t spin this in your favor you need to look for another job!!It'll happen. In addition to the above posts, think about the new Invokana HF data...no amputations, and the better data in reducing HF ...is much better than us. Seriously, we are a third class drug in the market. Combine that with less than HALF of the market share we used to have with Bydureon, and the recipe is this....theres alot -simply put- that we're not being told. Moving forward. ..I bet most of us will be clawing and begging just to get in the ballpark of a decent bonus check. Its not getting better, like the puppets tell us. Most I think would agree that selling these drugs are much more difficult than a couple years ago. Senior management , marketing, and managed care have really handed it to us.
I am.If you can’t spin this in your favor you need to look for another job!!
It'll happen. In addition to the above posts, think about the new Invokana HF data...no amputations, and the better data in reducing HF ...is much better than us. Seriously, we are a third class drug in the market. Combine that with less than HALF of the market share we used to have with Bydureon, and the recipe is this....theres alot -simply put- that we're not being told. Moving forward. ..I bet most of us will be clawing and begging just to get in the ballpark of a decent bonus check. Its not getting better, like the puppets tell us. Most I think would agree that selling these drugs are much more difficult than a couple years ago. Senior management , marketing, and managed care have really handed it to us.
The respiratory sleeve that’s promoting DSA is only helping our competitors.
Only according to Veeva